Usefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease

Toshimasa Nakada

Authors

Toshimasa Nakada

Keywords:

kawasaki disease, intravenous immuno-globulin therapy, coronary artery lesions, aspirin, flurbiprofen

Abstract

Kawasaki disease is an acute systemic vasculitis of unknown cause that affects mainly infants and children. Coronary artery lesions (CAL) are one of the most important complications of this disease. An appropriate therapy during acute phase of Kawasaki disease to prevent large CAL has not been established. Recent studies disclosed that aspirin and flurbiprofen appeared to have a negative impact on the suppressive effects of initial intravenous immunoglobulin (IVIG) therapy on CAL development in the acute phase of Kawasaki disease and that an initial single IVIG therapy with delayed administration of anti-inflammatory drugs might be useful for prevention of large CAL. Furthermore, recent study disclosed that variable factors including IVIG resistance, responsiveness, and relapse of disease were associated with CAL complications and that an initial single IVIG therapy may be useful for the prevention of large CAL caused by different factors of Kawasaki disease.

Downloads

How to Cite

Usefulness of an Initial Single Intravenous Immunoglobulin Therapy for Kawasaki Disease. (2015). Global Journal of Medical Research, 15(F4), 15-17. https://medicalresearchjournal.org/index.php/GJMR/article/view/993

Download Citation

References

Jane Burns, Mary Glodé (2004) Kawasaki syndrome. 364(9433), 533-544.

F Muller, W Knirsch, P Harpes, R Pretre, B Valsangiacomo, O Kretschmar (2009) Long-term follow-up of acute changes in coronary artery diameter caused by Kawasaki disease: risk factors for development of stenotic lesions. 98, 501-507.

E Tsuda, T Kamiya, Y Ono, K Kimura, K Kurosaki, S Echigo (2005) Incidence of Stenotic Lesions Predicted by Acute Phase Changes in Coronary Arterial Diameter During Kawasaki Disease. 26(1), 73-79.

T Nakada (2015) Prevention of large coronary artery lesions caused by Kawasaki disease.

Kenshi Furusho, Hiroyuki Nakano, Keisuke Shinomiya, Tokio Tamura, Yutaka Manabe, Masaharu Kawarano, Kiyoshi Baba, Tetsuro Kamiya, Nobuyuki Kiyosawa, Tadashi Hayashidera, Osamu Hirose, Tatsuo Yokoyama, Kunizo Baba, Chuzo Mori (1984) HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE. 324(8411), 1055-1058.

J Newburger, M Takahashi, A Beiser (1991) Single intravenous infusion of gamma globulin as compared with four infusion in the treatment of acute Kawasaki syndrome. 324, 1633-1639.

Pediatric Cardiology (2014) Cardiac Surgery committee for development of guidelines for medical treatment of acute Kawasaki disease. Guidelines for medical treatment of acute Kawasaki disease: report of the Research committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). 56, 135-158.

T Kobayashi, T Saji, T Otani (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. 379, 1613-1620.

Adriana Tremoulet, Sonia Jain, Preeti Jaggi, Susan Jimenez-Fernandez, Joan Pancheri, Xiaoying Sun, John Kanegaye, John Kovalchin, Beth Printz, Octavio Ramilo, Jane Burns (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. 383(9930), 1731-1738.

Toshimasa Nakada (2015) Background Factors Associated with the Complications of Coronary Artery Lesions Caused by Kawasaki Disease. 4(5), 127.

T Yahata, C Suzuki, A Yoshikawa (2014) Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. 78, 188-193.

J Baumer, Samantha Love, Amit Gupta, Linda Haines, Ian Maconochie, Jaspal Dua (2006) Salicylate for the treatment of Kawasaki disease in children. 2010(1), 4175.

K Hsieh, K Weng, C Lin (2004) Treatment of acute Kawasaki disease: aspirin's role in the febril stage revisited. 114, 689-e693.

Goni Lee, Seung Lee, Young Hong, Sejung Sohn (2013) Is High-Dose Aspirin Necessary in the Acute Phase of Kawasaki Disease?. 43(3), 182.

H Ito, N Kiyosawa (2002) Effectiveness of aspirin therapy in acute phase of Kawasaki disease. 22, 1640-1643.

T Nakada (2012) Difference in the prevalence of coronary arterial lesions in Kawasaki disease according to the time of initiation of additional aspirin or flurbiprofen therapy. 57, 15-19.

T Nakada (2015) Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease. 36, 335-339.

Chahid Benammar, Aziz Hichami, Akadiri Yessoufou, Anne-Marie Simonin, Meriem Belarbi, Hocine Allali, Naim Khan (2010) Zizyphus lotus L. (Desf.) modulates antioxidant activity and human T-cell proliferation. 10(1), 54.

Matthew Buckland, Giovanna Lombardi (2009) Aspirin and the Induction of Tolerance by Dendritic Cells. 188, 197-213.

L Huang, G Mackenzie, N Ouyang (2011) The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvantinduced arthritis in rats. 162, 1521-1533.

Y Inoue, T Kaifu, A Sugahata-Tobinai (2007) Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. 179, 764-774.

M Yamamoto, K Kobayashi, Y Ishikawa (2010) The inhibitory effects of intravenous administration of rabbit immunoglobulin G on airway inflammation are dependent upon Fcc receptor II b on CD11c(?) dendritic cells in a murine model. 162, 315-324.

Y Zhang, X Huang, M Kang (2006) Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease. 44, 329-332.

A Ashida, N Ozaki, K Kishi, H Katayama, K Okasora, H Tamai (2013) A case report of refractory Kawasaki disease with bilateral giant coronary aneurysms treated with intravenous immunoglobulin and prednisolone combination therapy. 33, 1471-1474.